Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia

Monitoring Minimal Residual Disease in Acute Myeloid Leukemia: Ready for Prime Time?

(2017) Farhad Ravandi et al.   Journal of the National Comprehensive Cancer Network

Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease–Based Definition of Complete Remission?

(2016) Daisuke Araki et al.   JOURNAL OF CLINICAL ONCOLOGY

Assessment of Minimal Residual Disease in Standard-Risk AML

(2016) Adam Ivey et al.   NEW ENGLAND JOURNAL OF MEDICINE

The clinical significance of negative flow cytometry immunophenotypic results in a morphologically scored positive bone marrow in patients following treatment for acute myeloid leukemia

(2015) Juan Ouyang et al.   AMERICAN JOURNAL OF HEMATOLOGY

Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study

(2015) Ching-Hon Pui et al.   LANCET ONCOLOGY

Acute Myeloid Leukemia

(2015) Hartmut Döhner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Multi-color flow cytometric immunophenotyping for detection of minimal residual disease in AML: past, present and future

(2014) J M Jaso et al.   BONE MARROW TRANSPLANTATION

Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia

(2013) Aziz Nazha et al.   AMERICAN JOURNAL OF HEMATOLOGY

Relapsed acute myeloid leukemia: Why is there no standard of care?

(2013) Farhad Ravandi   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial

(2013) H.-H. Zhu et al.   BLOOD

Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission

(2013) R. B. Walter et al.   BLOOD

Prognostic Relevance of Treatment Response Measured by Flow Cytometric Residual Disease Detection in Older Patients With Acute Myeloid Leukemia

(2013) Sylvie D. Freeman et al.   JOURNAL OF CLINICAL ONCOLOGY

High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study

(2013) Monique Terwijn et al.   JOURNAL OF CLINICAL ONCOLOGY

Minimal residual disease in acute myeloid leukaemia

(2013) Christopher S. Hourigan et al.   Nature Reviews Clinical Oncology

Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial

(2012) J. A. L. Yin et al.   BLOOD

Early clearance of peripheral blood blasts predicts response to induction chemotherapy in acute myeloid leukemia

(2012) Martha Arellano et al.   CANCER

Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia

(2012) Jay P. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Primary refractory acute myeloid leukaemia - in search of better definitions and therapies

(2011) Farhad Ravandi   BRITISH JOURNAL OF HAEMATOLOGY

Monitoring of Minimal Residual Disease in NPM1-Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group

(2011) Jan Krönke et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of Pretransplantation Minimal Residual Disease, As Detected by Multiparametric Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Myeloid Leukemia

(2011) Roland B. Walter et al.   JOURNAL OF CLINICAL ONCOLOGY

Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy

(2010) F. Ravandi et al.   BLOOD

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials

(2010) D. Grimwade et al.   BLOOD

Effect of Complete Remission and Responses Less Than Complete Remission on Survival in Acute Myeloid Leukemia: A Combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study

(2010) Roland B. Walter et al.   JOURNAL OF CLINICAL ONCOLOGY

Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial

(2010) Jeffrey E Rubnitz et al.   LANCET ONCOLOGY

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

(2009) H. Dohner et al.   BLOOD

Prospective Minimal Residual Disease Monitoring to Predict Relapse of Acute Promyelocytic Leukemia and to Direct Pre-Emptive Arsenic Trioxide Therapy

(2009) David Grimwade et al.   JOURNAL OF CLINICAL ONCOLOGY